查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018620

基於NGS的RNA定序市場：按產品、技術、應用和最終用戶分類－2026-2032年全球市場預測

NGS-Based RNA-Sequencing Market by Product, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基於 NGS 的 RNA 定序市值將達到 31.7 億美元，到 2026 年將成長到 37.7 億美元，到 2032 年將達到 112 億美元，年複合成長率為 19.74%。

主要市場統計數據
基準年 2025 31.7億美元
預計年份：2026年 37.7億美元
預測年份 2032 112億美元
複合年成長率 (%) 19.74%

全面介紹基於 NGS 的 RNA定序的創新及其對轉化研究、臨床流程和生物資訊整合的影響。

基於次世代定序（NGS）的RNA定序已從最初的科研興趣發展成為支持發現、診斷和治療方法研發的基礎平台。該技術能夠以高靈敏度和高解析度對轉錄組進行定量分析，並已應用於從生物標記鑑定到闡明細胞異質性等多種領域。隨著研究機構採用更複雜的工作流程和計算流程，RNA定序在從早期研究到臨床應用的決策過程中發揮日益關鍵的作用。

對改變 RNA定序實踐和轉化研究成果的關鍵技術、操作和協作變革進行詳細分析。

RNA定序的現況正受到多種因素的共同影響，而不僅僅是處理能力的提升。首先，從批量分析到單細胞和空間轉錄組學的轉變，揭示了細胞異質性和組織結構，從根本上改變了我們對生物學結果的解釋。這種轉變需要新的樣品製備方案、更精細的品管以及稀疏數據分析方法。因此，研究團隊現在在設計實驗時，會著眼於細胞層面的解析度，這影響到從試劑選擇到下游計算資源的各個層面。

我們將密切關注 2025 年關稅變化將如何影響整體RNA定序業務的供應鏈韌性、籌資策略和供應商關係。

影響關稅的政策變化會對整個生命科學供應鏈產生連鎖反應，進而影響成本、供應商關係和籌資策略。在試劑、儀器和專用耗材的跨國採購環境中，關稅上漲會推高商品總成本，促使企業重新評估籌資策略。許多實驗室面臨採購週期延長和庫存管理日益受到重視的問題。採購團隊正在優先考慮延長前置作業時間，並尋找替代供應商以減少供應中斷。

綜合細分分析，解釋應用程式、產品、最終用戶和技術如何組合形成客製化的工作流程、功能需求和策略重點。

從應用角度分析部署情況，可以清楚揭示影響需求和投資的用例。生物標記發現著重於早期識別和檢驗，因此需要高通量可重複性和嚴格的檢驗流程來支援下游臨床應用。藥物發現和開發則受到不同的限制。藥物動力學研究優先考慮定量準確性，標靶辨識需要廣泛的轉錄組覆蓋，而毒理學研究則優先考慮對罕見或低表達轉錄物的敏感性。基因表現譜分析包括適用於群體層級訊號的批量分析，以及用於揭示細胞和微環境細微差異的單細胞和空間分析。個人化醫療需要整合伴隨診斷和治療監測，以提供符合監管標準的、可操作的、針對特定患者的見解和證據。

對影響世界各地 RNA定序技術採用的能力生態系統、監管環境和夥伴關係模式進行必要的區域分析。

區域差異導致了獨特的技術應用模式和戰略重點。在美洲，由科研密集型機構和生物技術公司組成的緊密網路支撐著一個充滿活力的技術應用生態系統，促進了轉化研究合作和官民合作關係。這種環境有利於新型定序方法的快速應用，並推動儀器供應商與早期使用者之間的密切合作，而法律規範和報銷途徑則持續影響臨床應用的進程。

從企業層面提供可操作的觀點，探討競爭差異化、夥伴關係策略以及推動採用和長期客戶參與的能力投資。

RNA定序生態系統中的主要企業透過整合獨特的化學技術、儀器工程、軟體生態系統以及降低准入門檻的服務來脫穎而出。那些將強大的硬體、可擴充性的雲端分析能力和卓越的客戶支援相結合的公司，正在為高通量研究和臨床客戶創造持續的競爭優勢。此外，提供整合耗材和檢驗的工作流程的供應商能夠降低變異性並縮短結果獲取時間，這在臨床診斷和受監管的研究中尤其重要。

為領導者提供關鍵建議，以實現快速部署和風險緩解，包括技術選擇協調、工作流程標準化以及加強供應鏈和分析策略。

領導者首先應將研究目標與技術選擇相匹配，並確保所選定序方法（批量測序、單細胞測序、長讀長測序或空間定序）能夠直接解決關鍵的生物學挑戰。這種匹配可以減少下游流程中的重複工作，並最佳化資源分配。其次，各機構應投資於標準化的樣本工作流程和品管查核點，以確保不同地點和研究的結果可重複。這有助於提高人們對探索性研究和臨床結果的信心。

清楚地解釋用於得出見解的跨學科調查方法和檢驗框架，確保透明度、可重複性和可操作性。

本分析整合了來自對領域專家的訪談、對已發表方案的技術評估以及對同行評審文獻的系統性回顧，以全面檢驗相關趨勢和實際應用。我們從研究所所長、檢體採購經理和生物資訊學專家處收集了主要的定性信息，以了解實際操作情況和檢驗重點。技術評估包括對工作流程要素（例如樣品製備方法、讀長的影響和檢體品質閾值）進行基準測試，旨在為選擇合適的技術提供依據。

透過將技術創新、營運要求和策略路徑整合到簡潔的結論中，我們可以創建可重複且具有臨床意義的 RNA定序程序。

總之，RNA定序正處於技術創新和營運轉型的十字路口。單細胞、長讀長和空間轉錄組學的進步正在拓展可解決的生物學難題範圍，而不斷變化的價值鏈趨勢和監管環境則要求採購和專案管理採用新的方法。那些能夠將技術選擇與科學目標緊密結合、投資於可重複的工作流程並建立靈活夥伴關係的機構，將能夠最大限度地發揮這些進步的價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 基於NGS的RNA定序市場：依產品分類

  • 消耗品
    • 酵素
    • 試劑和試劑盒
  • 裝置
    • 數據分析平台
    • 樣品製備裝置
    • 序列器
  • 服務
    • 生物資訊分析服務
    • 專案管理服務
    • 樣品製備服務

第9章：基於NGS的RNA定序市場：依技術分類

  • 大量定序
  • 長讀長定序
  • 單細胞定序
  • 空間轉錄組學

第10章：基於NGS的RNA定序市場：依應用分類

  • 生物標記發現
    • 早期生物標記的鑑定
    • 檢驗
  • 藥物發現與開發
    • 藥物動力學研究
    • 目標識別
    • 毒性測試
  • 基因表現分析
    • 批量分析
    • 單細胞分析
    • 空間剖面分析
  • 個人化醫療
    • 伴隨診斷
    • 治療監測

第11章 基於NGS的RNA定序市場：依最終用戶分類

  • 學術機構及政府機構
    • 研究機構
    • 大學
  • 臨床診斷檢查室
    • 醫院檢查室
    • 獨立檢測實驗室
  • 合約研究機構
  • 製藥和生物技術公司
    • 生技公司
    • 製藥公司

第12章：基於NGS的RNA定序市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：基於NGS的RNA定序市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 以NGS為基礎的RNA定序市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基於NGS的RNA定序市場

第16章：中國基於NGS的RNA定序市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies
  • Astrea Bioseparations Ltd.
  • Azenta Life Sciences
  • Becton, Dickinson and Company
  • BGI Group
  • Brooks Automation Inc
  • DNASTAR, Inc.
  • Eurofins Scientific
  • F. Hoffmann-la Roche AG
  • Genewiz by Brooks Automation, Inc.
  • Genomnia srl
  • Hamilton Company
  • Illumina, Inc.
  • Merck KGaA
  • Microsynth AG
  • Mina INC
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • PerkinElmer, Inc.
  • Precigen, Inc
  • Psomagen Inc.
  • Qiagen NV
  • Seqomics Kft.
  • Takara Bio Inc.
  • Tecan genomics
  • Thermo Fisher Scientific
Product Code: MRR-2214614769D5

The NGS-Based RNA-Sequencing Market was valued at USD 3.17 billion in 2025 and is projected to grow to USD 3.77 billion in 2026, with a CAGR of 19.74%, reaching USD 11.20 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.17 billion
Estimated Year [2026] USD 3.77 billion
Forecast Year [2032] USD 11.20 billion
CAGR (%) 19.74%

Comprehensive introduction to NGS-based RNA sequencing innovations and their implications for translational research clinical pipelines and bioinformatics integration

Next-generation sequencing (NGS)-based RNA sequencing has progressed from an academic curiosity to a foundational platform that underpins discovery, diagnostics, and therapeutic development. The technique's capacity to quantify transcriptomes with high sensitivity and resolution now supports diverse applications ranging from biomarker identification to the interrogation of cellular heterogeneity. As laboratories adopt more sophisticated workflows and computational pipelines, RNA sequencing increasingly informs decisions across early-stage research and clinical translation.

In addition, innovations in library preparation, read-length optimization, and multi-modal integration have expanded the utility of RNA sequencing in complex biological contexts. These technical advances have been accompanied by shifts in laboratory practices, heightened expectations for reproducible analyses, and new demands for regulatory alignment. Consequently, leaders in academia, diagnostics, and industry must understand not only the technology, but also operational considerations such as sample handling, data governance, and cross-disciplinary collaboration.

This introduction frames the discussion for stakeholders who need to align scientific capabilities with strategic objectives. It highlights why RNA sequencing is now a central asset in translational pipelines, and it outlines the contours of the landscape that follow in subsequent sections.

Detailed analysis of the major technological operational and collaborative shifts that are transforming RNA sequencing practices and translational research outcomes

The landscape of RNA sequencing has been reshaped by several convergent forces that extend beyond raw throughput improvements. First, the move from bulk to single-cell and spatial transcriptomics has fundamentally changed biological interpretation by illuminating cellular heterogeneity and tissue architecture. This transition has demanded new sample preparation protocols, refined quality controls, and analytical methods capable of resolving sparse data. As a result, research teams now design experiments with cellular resolution in mind, which influences everything from reagent selection to downstream computational resources.

Second, long-read sequencing technologies have emerged as a complementary approach, enabling the detection of full-length isoforms and complex transcript structures that short reads can miss. This capability is accelerating our understanding of alternative splicing, fusion transcripts, and transcript isoform regulation, which in turn informs target validation and biomarker refinement. The adoption of long-read approaches also requires reassessment of library construction workflows and data storage approaches because of differing error profiles and data formats.

Third, integration with multi-omics and cloud-enabled bioinformatics platforms is driving collaborative, reproducible analyses across institutions. As workflows become modular and interoperable, teams can combine transcriptomic data with proteomics and epigenomics to generate higher-confidence biological hypotheses. Taken together, these shifts are not merely technical; they alter how organizations prioritize investments, structure collaborations, and translate discovery into clinical application.

Rigorous exploration of how tariff shifts in 2025 could reshape supply chain resilience procurement strategies and vendor relationships across RNA sequencing operations

Policy changes that affect tariffs can ripple through the life sciences supply chain, influencing costs, supplier relationships, and procurement strategies. In contexts where reagents, instruments, and specialized consumables cross borders, higher duties increase the landed cost of goods and create incentives to revisit sourcing strategies. For many laboratories, this results in longer procurement cycles and elevated attention to inventory management, with procurement teams prioritizing longer lead times and alternative suppliers to mitigate supply interruptions.

Moreover, tariffs can accelerate localization and near-shoring efforts as institutions and vendors seek to reduce exposure to cross-border duties and currency volatility. Suppliers may respond by establishing regional manufacturing hubs or by optimizing their product portfolios to reduce the number of tariff-affected components. In parallel, service providers and contract research organizations may adapt by offering bundled, end-to-end solutions that absorb some supply chain risks on behalf of customers, thereby simplifying procurement for research and clinical laboratories.

Consequently, research groups must reassess vendor contractual terms, explore multi-sourcing, and consider the total cost of ownership when selecting instruments and consumables. In addition, strategic purchasing decisions will increasingly weigh supply continuity, regional support, and the flexibility to pivot between reagents or platforms without compromising data comparability. Ultimately, tariff-related pressures are prompting organizations to adopt more resilient supply chain strategies and a greater emphasis on partnership models that balance cost, reliability, and performance.

Integrated segmentation analysis explaining how applications products end users and technologies combine to shape tailored workflows capability needs and strategic priorities

Analyzing adoption through the lens of application reveals distinct use-cases that shape requirements and investments. Biomarker discovery, with its focus on early-stage identification and validation, demands high-throughput reproducibility and rigorous validation pipelines to support downstream clinical translation. Drug discovery and development imposes orthogonal constraints: pharmacokinetic studies emphasize quantitative precision, target identification requires broad transcriptome coverage, and toxicology studies prioritize sensitivity for rare or low-abundance transcripts. Gene expression profiling spans bulk approaches suited to population-level signals as well as single-cell and spatial profiling that reveal cellular and microenvironmental nuances. Personalized medicine requires integration across companion diagnostics and therapeutic monitoring to deliver actionable, patient-specific insights and regulatory-grade evidence.

From a product perspective, consumables such as enzymes, reagents and kits determine assay sensitivity and consistency, while instruments including library preparation platforms, sequencers and data analysis platforms define throughput, read quality, and workflow automation. Services layer adds further value through bioinformatics analysis, project management, and sample preparation expertise that reduce adoption friction and accelerate time-to-insight. These product and service distinctions influence procurement strategies and the division of labor across internal teams and external partners.

End users exhibit varied priorities that influence solution design and support models. Academic and government research entities-comprising research institutes and universities-prioritize methodological flexibility and novel applications, whereas clinical diagnostics laboratories including hospital and independent labs emphasize regulatory compliance, sample traceability, and turnaround times. Contract research organizations operate on delivery-driven models that require scalable workflows and robust quality management, and pharmaceutical and biotechnology companies balance discovery throughput with the rigor needed for preclinical and clinical development.

Technology segmentation underscores that bulk sequencing remains a workhorse for population and cohort studies, long-read sequencing provides unmatched isoform and structural insights, single-cell sequencing resolves cellular heterogeneity, and spatial transcriptomics captures tissue context. Each technology imposes different requirements for experimental design, data processing, and interpretation, and successful programs calibrate their investments to match the specific scientific question while ensuring interoperability where multi-technology strategies are employed.

Essential regional analysis of capability ecosystems regulatory landscapes and partnership models that influence the adoption of RNA sequencing innovations across global territories

Regional differences drive distinct adoption patterns and strategic priorities. In the Americas, research-intensive institutions and a dense network of biotechnology companies support a vibrant ecosystem for technology adoption, translational collaborations, and private-public partnerships. This environment encourages rapid deployment of new sequencing modalities and close engagement between instrument vendors and early adopters, while regulatory frameworks and reimbursement pathways continue to influence clinical translation timelines.

Europe, the Middle East and Africa present a heterogeneous landscape in which regulatory harmonization efforts, cross-border research consortia, and national funding initiatives shape capacity building. Many countries in this region invest strategically in infrastructure to support genomic medicine and translational research, creating opportunities for consortium-driven studies and regional manufacturing or distribution partnerships. Meanwhile, disparate regulatory regimes encourage solutions that emphasize interoperability, data protection, and cross-jurisdictional compliance.

Asia-Pacific demonstrates a strong emphasis on scale, localization, and rapid uptake of innovative workflows, with significant investments in both academic centers and commercial biotech. Regional priorities often include building domestic manufacturing capability, expanding clinical sequencing services, and integrating digital health platforms. Consequently, companies and institutions operating across these regions must tailor their engagement strategies to account for differences in procurement practices, regulatory expectations, and local partnerships that support deployment at scale.

Actionable company-level perspectives on competitive differentiation partnership strategies and capability investments that drive adoption and long-term customer engagement

Leading organizations in the RNA sequencing ecosystem differentiate through a combination of proprietary chemistry, instrument engineering, software ecosystems, and services that lower barriers to adoption. Companies that pair robust hardware with scalable cloud-enabled analysis and strong customer support create durable advantages for high-throughput research and clinical customers. In addition, vendors that offer integrated consumables and validated workflows reduce variability and accelerate time-to-results, which is particularly valuable for clinical diagnostics and regulated studies.

Partnerships between instrument providers, reagent manufacturers, and bioinformatics firms have produced more end-to-end solutions that appeal to organizations seeking turnkey capabilities. Strategic alliances with contract research organizations and academic consortia further extend reach into specialized applications such as spatial transcriptomics and single-cell analytics. Meanwhile, service-focused firms that provide deep bioinformatics expertise and sample handling capabilities help bridge gaps for institutions that lack in-house computational resources.

As competitive dynamics evolve, companies that invest in interoperability, open APIs, and community-driven analysis frameworks are better positioned to capture long-term engagement from research networks. Equally important is the ability to demonstrate real-world utility through peer-reviewed validations and regulatory-compliant studies that verify performance in clinically relevant settings. These company-level strategies are central to shaping adoption, partner selection, and customer retention across the ecosystem.

High-impact recommendations for leaders to align technology selection standardize workflows and strengthen supply chain and analytics strategies for rapid adoption and risk mitigation

Leaders should begin by aligning research objectives with technology selection, ensuring that the chosen sequencing approach-bulk, single-cell, long-read, or spatial-directly addresses the primary biological question. This alignment reduces downstream rework and optimizes resource allocation. Next, organizations should invest in standardized sample workflows and quality-control checkpoints that enable reproducible outcomes across sites and studies, thereby enhancing confidence in both discovery and clinical results.

To mitigate supply chain and procurement risks, institutions should cultivate multi-vendor relationships and explore regional sourcing options that can provide continuity under shifting trade policies. Concurrently, building internal bioinformatics capacity while leveraging external service partners for specialized analyses creates a hybrid model that balances control with scalability. Investing in interoperable data infrastructures and clear data governance policies will facilitate multi-omics integration, collaboration, and compliance with regional regulations.

Finally, industry leaders should prioritize transparent validation studies and regulatory engagement early in the development lifecycle. Demonstrating clinical utility and robustness through rigorous, externally validated studies accelerates stakeholder buy-in and supports downstream adoption. By following these prioritized actions, organizations can extract greater value from RNA sequencing technologies while reducing operational and strategic risk.

Clear explanation of the multidisciplinary research methodology and validation framework used to derive insights ensuring transparency reproducibility and actionable relevance

The analysis synthesizes insights from primary interviews with domain experts, technical evaluation of published protocols, and systemic review of peer-reviewed literature to triangulate trends and practical implications. Primary qualitative inputs were obtained from laboratory directors, procurement leads, and bioinformatics specialists to capture operational realities and validation priorities. Technical assessments included benchmarking of workflow elements such as library preparation methods, read-length implications, and sample quality thresholds to contextualize technology fit for purpose.

Analytical methods emphasize reproducibility and traceability: key assertions were validated against multiple independent sources and methodological limitations were explicitly noted. Comparative assessments focused on capability differentiation rather than quantitative market metrics, and case studies were used to illustrate how technology choices influenced outcomes across discovery and clinical workflows. Where appropriate, regulatory documents and publicly available guidance informed considerations around clinical implementation and compliance.

This methodology aims to provide readers with a transparent basis for the findings and recommendations presented, and it supports informed decision-making by highlighting both technical nuances and practical constraints that affect deployment and adoption of RNA sequencing technologies.

Concise concluding synthesis linking technological innovation operational imperatives and strategic pathways to enable reproducible and clinically relevant RNA sequencing programs

In closing, RNA sequencing stands at the confluence of technological innovation and operational transformation. Advances in single-cell, long-read, and spatial transcriptomics are expanding the scope of biological questions that can be addressed, while evolving supply chain dynamics and regulatory landscapes require new approaches to procurement and program management. Organizations that thoughtfully align technology choices with scientific objectives, invest in reproducible workflows, and build flexible partnerships will be best positioned to capture the value of these advances.

Moving forward, the most successful programs will integrate robust bioinformatics, prioritize cross-disciplinary collaboration, and prepare for regulatory and commercial constraints that influence clinical translation. By adopting resilient supply strategies and investing in validation pathways, stakeholders can accelerate the translation of transcriptomic insights into actionable clinical and research outcomes. This conclusion underscores the need for strategic planning that bridges innovation, practicality, and compliance to enable sustainable impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. NGS-Based RNA-Sequencing Market, by Product

  • 8.1. Consumables
    • 8.1.1. Enzymes
    • 8.1.2. Reagents And Kits
  • 8.2. Instruments
    • 8.2.1. Data Analysis Platforms
    • 8.2.2. Library Prep Instruments
    • 8.2.3. Sequencers
  • 8.3. Services
    • 8.3.1. Bioinformatics Analysis Services
    • 8.3.2. Project Management Services
    • 8.3.3. Sample Preparation Services

9. NGS-Based RNA-Sequencing Market, by Technology

  • 9.1. Bulk Sequencing
  • 9.2. Long-Read Sequencing
  • 9.3. Single-Cell Sequencing
  • 9.4. Spatial Transcriptomics

10. NGS-Based RNA-Sequencing Market, by Application

  • 10.1. Biomarker Discovery
    • 10.1.1. Early-Stage Biomarker Identification
    • 10.1.2. Validation
  • 10.2. Drug Discovery & Development
    • 10.2.1. Pharmacokinetic Studies
    • 10.2.2. Target Identification
    • 10.2.3. Toxicology Studies
  • 10.3. Gene Expression Profiling
    • 10.3.1. Bulk Profiling
    • 10.3.2. Single-Cell Profiling
    • 10.3.3. Spatial Profiling
  • 10.4. Personalized Medicine
    • 10.4.1. Companion Diagnostics
    • 10.4.2. Therapeutic Monitoring

11. NGS-Based RNA-Sequencing Market, by End User

  • 11.1. Academic & Government
    • 11.1.1. Research Institutes
    • 11.1.2. Universities
  • 11.2. Clinical Diagnostics Laboratories
    • 11.2.1. Hospital Laboratories
    • 11.2.2. Independent Laboratories
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical & Biotechnology Companies
    • 11.4.1. Biotechnology Companies
    • 11.4.2. Pharmaceutical Companies

12. NGS-Based RNA-Sequencing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. NGS-Based RNA-Sequencing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. NGS-Based RNA-Sequencing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States NGS-Based RNA-Sequencing Market

16. China NGS-Based RNA-Sequencing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies
  • 17.6. Astrea Bioseparations Ltd.
  • 17.7. Azenta Life Sciences
  • 17.8. Becton, Dickinson and Company
  • 17.9. BGI Group
  • 17.10. Brooks Automation Inc
  • 17.11. DNASTAR, Inc.
  • 17.12. Eurofins Scientific
  • 17.13. F. Hoffmann-la Roche AG
  • 17.14. Genewiz by Brooks Automation, Inc.
  • 17.15. Genomnia srl
  • 17.16. Hamilton Company
  • 17.17. Illumina, Inc.
  • 17.18. Merck KGaA
  • 17.19. Microsynth AG
  • 17.20. Mina INC
  • 17.21. Oxford Nanopore Technologies
  • 17.22. Pacific Biosciences of California, Inc.
  • 17.23. PerkinElmer, Inc.
  • 17.24. PerkinElmer, Inc.
  • 17.25. Precigen, Inc
  • 17.26. Psomagen Inc.
  • 17.27. Qiagen N.V.
  • 17.28. Seqomics Kft.
  • 17.29. Takara Bio Inc.
  • 17.30. Tecan genomics
  • 17.31. Thermo Fisher Scientific

LIST OF FIGURES

  • FIGURE 1. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 270. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 272. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 273. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 275. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 278. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 279. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 280. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 283. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 284. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION NGS-BASED RNA-SEQUENCIN